Article content
Third quarter revenue of $32.0 million, up 3.8% from the previous quarter adjusting for removal of MedMen NY Inc. from continuing operations
Total Retail Revenue increase of 8.2% quarter-over-quarter, inclusive of New York and Arizona stores
Total Retail Adjusted EBITDA increased to $8.5 million from $6.0 million quarter-over-quarter, for a 22.5% margin, and Total Retail Adjusted EBITDA from continuing operations increased to $7.4 million from $5.5 million quarter-over-quarter for a 23.3% margin
LOS ANGELES MedMen Enterprises Inc. (
“MedMen” or the
“Company”) (CSE: MMEN) (OTCQX: MMNFF), a cannabis retailer with operations across the United States, today released its consolidated financial results for its third quarter fiscal 2021 ending March 27, 2021. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.
Greetings, and welcome to the Hain Celestial Third Quarter 2021 Earnings Conference Call. [Operator Instructions]
It is now my pleasure to introduce your host, Anna Kate Heller. Thank you, Anna Kate. You may begin.
Anna Kate Heller
Investor Relations
Thank you. Good morning, and thank you for joining us on Hain Celestial s Third Quarter Fiscal Year 2021 Earnings Conference Call. On the call today are Mark Schiller, President and Chief Executive Officer; and Javier Idrovo, Executive Vice President and Chief Financial Officer. During the course of this call, management may make forward-looking statements within the meaning of the federal securities laws. These include expectations and assumptions regarding the company s future operations and financial performance, including expectations and assumptions related to the impact of the COVID-19 pandemic. These statements are based on management s current expectations and involve risks and uncertainties that could differ materially fr
MEI Pharma Reports Third Quarter Fiscal 2021 Results and Operational Highlights
-Topline TIDAL Study Data Evaluating Zandelisib in Relapsed or Refractory Follicular Lymphoma on Track to be Reported in the Fourth Quarter-
- MEI Maintains Strong Financial Position with ~$164 Million in Cash-
News provided by
Share this article
Share this article
SAN DIEGO, May 6, 2021 /PRNewswire/ MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for the quarter ended March 31, 2021 and highlighted recent corporate progress. The first several months of 2021 have been very eventful for MEI, highlighted by the completion of enrollment in the follicular lymphoma efficacy population arm of the zandelisib TIDAL study. In addition, we recently reported preclinical data at AACR 2021, demonstrating the ability of voruciclib to downregulate MYC and synergize with KRAS inhibitors in KRAS mutant cancers, said Da
Operator
Good day, and welcome to the Cardinal Health, Inc. Third Quarter Fiscal Year 2021 Earnings Conference Call. [Operator Instructions]
At this time, I would like to turn the conference over to Kevin Moran, Vice President of Investor Relations. Please go ahead.
Kevin Moran
Vice President of Investor Relations
Good morning, and welcome. Today, we will discuss Cardinal Health s third quarter fiscal 2021 results, along with an update to our FY 21 outlook. You can find today s press release and presentation on the IR section of our website at ir.cardinalhealth.com. Joining me today are Mike Kaufmann, Chief Executive Officer; and Jason Hollar, Chief Financial Officer. During the call, we will be making forward-looking statements. The matters addressed in the statements are subject to the risks and uncertainties that could cause actual results to differ materially from those projected or implied. Please refer to our SEC filings and the forward-looking statement slide at the b
MEI Pharma Reports Third Quarter Fiscal 2021 Results and Operational Highlights
-Topline TIDAL Study Data Evaluating Zandelisib in Relapsed or Refractory Follicular Lymphoma on Track to be Reported in the Fourth Quarter-
- MEI Maintains Strong Financial Position with ~$164 Million in Cash-
News provided by
Share this article
Share this article
SAN DIEGO, May 6, 2021 /PRNewswire/ MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for the quarter ended March 31, 2021 and highlighted recent corporate progress. The first several months of 2021 have been very eventful for MEI, highlighted by the completion of enrollment in the follicular lymphoma efficacy population arm of the zandelisib TIDAL study. In addition, we recently reported preclinical data at AACR 2021, demonstrating the ability of voruciclib to downregulate MYC and synergize with KRAS inhibitors in KRAS mutant cancers, said Da